bpc-157 and mots-c FDA Advisory Panel Votes to Loosen Rules on BPC-157, TB-500, Despite Agency Scientists' Opposition BPC 157 (Body Protection Compound-157)

Because large human studies remain limited, the full interaction profile of BPC-157 has not been established

It is important to accomplish the stick in one, rapid movement

Tape it to your refrigerator

Thank you, Heather! - Elena S.

Become a Member or sign in to Huberman Lab Premium Huberman Lab Essentials are short episodes focused on essential science and protocol takeaways from past full-length Huberman Lab episodes

What This Means for Patients and Prescribers For individuals using peptide therapies under physician supervision: More pharmacy options : Physicians prescribing BPC-157, MOTS-C, or other affected peptides should find more pharmacies willing to fill the prescription Better quality control : Legitimate compounding pharmacies must meet sterility, potency, and endotoxin testing standards that gray-market sources typically don't Lower costs : Competition among compounding pharmacies typically drives prices down versus single-source gray-market procurement Telehealth access : Peptide-prescribing telehealth services that stopped offering these compounds due to pharmacy access problems may resume For those using peptides sourced from research chemical vendors: the gray market will likely shrink as legitimate compounding access improves